"10.1371_journal.pone.0062784","plos one","2013-04-30T00:00:00Z","Déborah Ley; Niamh Harraghy; Valérie Le Fourn; Solenne Bire; Pierre-Alain Girod; Alexandre Regamey; Florence Rouleux-Bonnin; Yves Bigot; Nicolas Mermod","Institute of Biotechnology, University of Lausanne, and Center for Biotechnology UNIL-EPFL, Lausanne, Switzerland; Selexis SA, Geneva, Switzerland; PRC, UMR INRA-CNRS 7247, Centre INRA Val de Loire, Nouzilly, France; GICC, UMR CNRS 7292, UFR de Médecine, Tours, France","Conceived and designed the experiments: NM PAG YB FRB. Performed the experiments: DL VLF NH SB AR. Analyzed the data: DL VLF NH SB AR NM PAG YB FRB. Contributed reagents/materials/analysis tools: SB YB FRB VLF AR PAG. Wrote the paper: DL NH NM.","The authors have the following interests. This study was partly funded by Selexis SA, the employer of Valérie Le Fourn, Pierre-Alain Girod and Alexandre Regamey. Some of the authors own shares of Selexis SA, a company that uses proprietary technology to generate therapeutic-producing CHO cell lines. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","04","Déborah Ley","DL",9,TRUE,4,5,9,3,TRUE,TRUE,FALSE,0,NA,FALSE
